Korrektur
Correction to: Osimertinib-induced erythema dyschromicum perstans
Clinical and Experimental Dermatology · 17.08.2026 · 51 (9) · 1801-1801
DOI: 10.1093/ced/llag239 ↗Kurz gefasst
Korrektur in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 12.06.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to: Osimertinib-induced erythema dyschromicum perstans. Clinical and Experimental Dermatology, 51(9), 1801-1801. https://doi.org/10.1093/ced/llag239
Vancouver
Correction to: Osimertinib-induced erythema dyschromicum perstans. Clinical and Experimental Dermatology. 2026;51(9):1801-1801. doi:10.1093/ced/llag239
BibTeX
@article{euvimed2026,
title = {Correction to: Osimertinib-induced erythema dyschromicum perstans},
journal = {Clinical and Experimental Dermatology},
year = {2026},
volume = {51},
number = {9},
pages = {1801--1801},
doi = {10.1093/ced/llag239}
}
EUVIMED